Trial Profile
Low anticoagulant heparin (sevuparin/DF02) as adjunctive therapy in moderate to severe P. falciparum malaria. A phase II multi-centre, randomized, placebo-controlled, double blind study. - Nil
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2016
Price :
$35
*
At a glance
- Drugs Sevuparin (Primary)
- Indications Falciparum malaria
- Focus Adverse reactions
- Sponsors Modus Therapeutics
- 14 Dec 2015 Status changed from suspended to discontinued.
- 14 Dec 2015 New trial record